SEMNUR PHARMACEUTICALS

Serial Number 88503719
606

Registration Progress

Application Filed
Jul 8, 2019
Under Examination
Jan 14, 2020
Approved for Publication
Nov 19, 2019
Published for Opposition
Nov 19, 2019
Registered

Re-Apply for This Trademark

This trademark is no longer active. You may be able to file a new application for the same or similar mark.
Mark: SEMNUR PHARMACEUTICALS
Previous Owner: Semnur Pharmaceuticals, Inc.
Classes: 005

Trademark Image

SEMNUR PHARMACEUTICALS

Basic Information

Serial Number
88503719
Filing Date
July 8, 2019
Published for Opposition
November 19, 2019
Abandonment Date
February 20, 2023
Drawing Code
4000

Status Summary

Current Status
Inactive
Status Code
606
Status Date
Feb 20, 2023
Classes
005

Rights Holder

Semnur Pharmaceuticals, Inc.

03
Address
301 N. Whisman Road, Suite 100
Mountain View, CA 94043

Ownership History

Semnur Pharmaceuticals, Inc.

Original Applicant
03
Mountain View, CA

Semnur Pharmaceuticals, Inc.

Owner at Publication
03
Mountain View, CA

Legal Representation

Attorney
John Paul Oleksiuk

USPTO Deadlines

No Upcoming Deadlines

No upcoming deadlines found for this trademark.

Application History

40 events
Date Code Type Description Documents
Feb 21, 2023 MAB6 E ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED Loading...
Feb 20, 2023 ABN6 S ABANDONMENT - NO USE STATEMENT FILED Loading...
May 25, 2022 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
May 24, 2022 EX5G S SOU EXTENSION 5 GRANTED Loading...
May 20, 2022 EXT5 S SOU EXTENSION 5 FILED Loading...
May 24, 2022 AITU A CASE ASSIGNED TO INTENT TO USE PARALEGAL Loading...
May 20, 2022 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Dec 21, 2021 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Dec 17, 2021 EX4G S SOU EXTENSION 4 GRANTED Loading...
Dec 17, 2021 EXT4 S SOU EXTENSION 4 FILED Loading...
Dec 17, 2021 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Jun 22, 2021 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Jun 18, 2021 EX3G S SOU EXTENSION 3 GRANTED Loading...
Jun 18, 2021 EXT3 S SOU EXTENSION 3 FILED Loading...
Jun 18, 2021 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Dec 18, 2020 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Dec 16, 2020 EX2G S SOU EXTENSION 2 GRANTED Loading...
Dec 16, 2020 EXT2 S SOU EXTENSION 2 FILED Loading...
Dec 16, 2020 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Jul 15, 2020 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Jul 13, 2020 EX1G S SOU EXTENSION 1 GRANTED Loading...
Jul 13, 2020 EXT1 S SOU EXTENSION 1 FILED Loading...
Jul 13, 2020 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Jan 14, 2020 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
Nov 19, 2019 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Nov 19, 2019 PUBO A PUBLISHED FOR OPPOSITION Loading...
Oct 30, 2019 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Oct 10, 2019 ALIE A ASSIGNED TO LIE Loading...
Oct 7, 2019 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Sep 30, 2019 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Sep 27, 2019 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Sep 27, 2019 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Sep 26, 2019 ARAA I ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED Loading...
Sep 26, 2019 REAP I TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED Loading...
Sep 26, 2019 GPRN O NOTIFICATION OF PRIORITY ACTION E-MAILED Loading...
Sep 26, 2019 GPRA F PRIORITY ACTION E-MAILED Loading...
Sep 26, 2019 CPRA R PRIORITY ACTION WRITTEN Loading...
Sep 24, 2019 DOCK D ASSIGNED TO EXAMINER Loading...
Jul 16, 2019 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Jul 11, 2019 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
Pain relief medication; preparations for the relief of pain; injectable pharmaceutical gels for treatment of back pain, including lumbosacral radicular pain and sciatica; dexamethasone sodium phosphate for medical use for use in the treatment of pain; dexamethasone sodium phosphate gel for medical use
First Use Anywhere: 0
First Use in Commerce: 0

Classification

International Classes
005

Disclaimers

The following terms have been disclaimed and are not claimed as part of the trademark:
General Disclaimer
"PHARMACEUTICALS"